OncoHost, a technology company focused on precision medicine, announced on Monday that the Business Intelligence Group has named OncoHost as a winner in the 2026 BIG Innovation Awards in the Health category.
Additionally, OncoHost was selected as a Top 10 Innovator – Small Business, reflecting the company's leadership in developing clinically impactful technologies.
OncoHost was recognised for its PROphet platform, an AI-driven plasma-proteomics solution designed to help oncologists predict clinical benefit and therapy-related toxicity from a single pre-treatment blood test. Its first commercial offering, PROphetNSCLC, guides first-line immunotherapy decision-making in metastatic non-small cell lung cancer (NSCLC) by revealing host-response insights that extend beyond tumour-only biomarkers.
The BIG Innovation Awards are designed to honour organisations, products, and leaders transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.
Profusa launches Lumee tissue oxygen system for CRO market
OncoHost receives BIG Innovation Award in Health category
Hoth Therapeutics achieves European regulatory milestone for HT-001
AVEO Oncology reports first patient dosed in front-line AML combination study of ficlatuzumab
Rakuten Medical signs manufacturing agreement with LOTTE Biologics
Curasight reports preliminary data from Phase 1 trial in patients with high-grade gliomas
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel